Plain-English translation of NCT06220188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
[177Lu]Lu-PSMAI&T is a radioactive medication designed to find and destroy prostate cancer cells that express a specific protein marker. This trial tests whether two infusions of this medication—given six weeks apart—can help men whose PSA levels are rising after surgery or radiation but who don't have visible cancer recurrence on scans. The goal is to understand whether treating patients at this earlier stage might improve outcomes.
When prostate cancer returns after initial treatment, it often shows up first as a rising PSA level before any tumors become visible on standard imaging. Currently, there are limited options for patients at this early biochemical stage, and doctors want to learn whether using this new radioactive therapy earlier might prevent the cancer from progressing further.
You likely qualify if…
You likely don't qualify if…
You would receive two intravenous infusions of the radioactive medication, spaced six weeks apart. The first dose is smaller (3 gigabecquerels) and the second is larger (6 gigabecquerels). Between and after the infusions, you will have blood tests and imaging scans to monitor your PSA levels and how your body responds to the treatment. The trial involves one medical center in Vienna, and you would need to visit for each infusion and follow-up assessment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Austria
Phase
Testing effectiveness
Sponsor
Medical University of Vienna
Enrollment target
~20 participants
Started
January 2024
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in February 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sazan Rasul, PhD
Medical University of Vienna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.